# Chinese biotech industry

Type: industry

Source: GetYourBrief — https://getyourbrief.com/entity/chinese-biotech-industry
Canonical HTML page: https://getyourbrief.com/entity/chinese-biotech-industry

## Timeline

- **2026-06-22**: NMPA releases 2025 report — China's National Medical Products Administration publishes comprehensive statistics on the record-breaking clinical trial activity.
- **2026-02**: Cost advantages quantified — At the Outsourcing in Clinical Trials conference in California, China's trial costs were reported 50–60% lower and timelines faster than in the US.
- **2025**: Record trial count achieved — 5,215 clinical drug trials registered, more than double 2020, with 57.5% being new drug trials and cancer treatments dominating.
- **2020**: Pre-surge baseline — Approximately 2,600 clinical drug trials registered in China (implied by 2025 doubling).

## Recent coverage (2 stories, network-wide)

### 5,215 China Trials in 2025 Cost 60% Less Than US: Security Risks Loom
2026-06-24 10:39:39 · Sector: health · Sentiment: Neutral · Impact: 7/10 · Sources: 2

China’s clinical drug trials hit a record 5,215 in 2025, with costs 50–60% lower than in the US. This surge, driven by Beijing’s biotech ambitions, is reshaping global drug development and raising national security concerns in Washington as Chinese firms gain dominance in cancer and vaccine research.
Full story: https://gethealthbrief.com/story/china-record-drug-trials-2025-cost-security

### China’s 5,215 Clinical Trials in 2025 Double Since 2020; Cancer Drugs Lead Surge
2026-06-24 10:39:00 · Sector: bio · Sentiment: Neutral · Impact: 7/10 · Sources: 2

With 5,215 clinical drug trials registered in 2025, China has more than doubled its pipeline since 2020, with 57.5% focused on novel drugs and cancer treatments topping the list. The rapid expansion and 50–60% cost advantage compared to the US are reshaping the global biopharma landscape, but Washington is scrutinizing implications for drug quality and security.
Full story: https://getbiobrief.com/story/china-5215-clinical-trials-2025-oncology-lead

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.